173 related articles for article (PubMed ID: 28645444)
21. Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia.
Sorigue M; Espasa A; Zamora L; Junca J
Ann Hematol; 2020 May; 99(5):1135-1136. PubMed ID: 32170360
[No Abstract] [Full Text] [Related]
22. High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia.
Patel SS; Pinkus GS; Ritterhouse LL; Segal JP; Dal Cin P; Restrepo T; Harris MH; Stone RM; Hasserjian RP; Weinberg OK
Am J Hematol; 2019 Aug; 94(8):921-928. PubMed ID: 31148220
[TBL] [Abstract][Full Text] [Related]
23. Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory.
Blombery P; Jones K; Doig K; Ryland G; McBean M; Thompson E; Yannakou CK; Westerman D
Arch Pathol Lab Med; 2018 May; 142(5):606-612. PubMed ID: 29425073
[TBL] [Abstract][Full Text] [Related]
24. Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia.
Scholl S; Mügge LO; Landt O; Loncarevic IF; Kunert C; Clement JH; Höffken K
Leuk Res; 2007 Sep; 31(9):1205-11. PubMed ID: 17306368
[TBL] [Abstract][Full Text] [Related]
25. Measurable residual disease testing for personalized treatment of acute myeloid leukemia.
Ehinger M; Pettersson L
APMIS; 2019 May; 127(5):337-351. PubMed ID: 30919505
[TBL] [Abstract][Full Text] [Related]
26. Rapid and sensitive typing of NPM1 mutations using LNA-mediated PCR clamping.
Thiede C; Creutzig E; Illmer T; Schaich M; Heise V; Ehninger G; Landt O
Leukemia; 2006 Oct; 20(10):1897-9. PubMed ID: 17041639
[No Abstract] [Full Text] [Related]
27. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
Balsat M; Renneville A; Thomas X; de Botton S; Caillot D; Marceau A; Lemasle E; Marolleau JP; Nibourel O; Berthon C; Raffoux E; Pigneux A; Rodriguez C; Vey N; Cayuela JM; Hayette S; Braun T; Coudé MM; Terre C; Celli-Lebras K; Dombret H; Preudhomme C; Boissel N
J Clin Oncol; 2017 Jan; 35(2):185-193. PubMed ID: 28056203
[TBL] [Abstract][Full Text] [Related]
28. A mind map for managing minimal residual disease in acute myeloid leukemia.
Benton CB; Ravandi F
Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419
[TBL] [Abstract][Full Text] [Related]
29. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor.
Papadaki C; Dufour A; Seibl M; Schneider S; Bohlander SK; Zellmeier E; Mellert G; Hiddemann W; Spiekermann K
Br J Haematol; 2009 Feb; 144(4):517-23. PubMed ID: 19055671
[TBL] [Abstract][Full Text] [Related]
30. Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning.
Gronlund JK; Veigaard C; Juhl-Christensen C; Skou AS; Melsvik D; Ommen HB
Eur J Haematol; 2024 Apr; 112(4):601-610. PubMed ID: 38197567
[TBL] [Abstract][Full Text] [Related]
31. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations.
Thol F; Kölking B; Damm F; Reinhardt K; Klusmann JH; Reinhardt D; von Neuhoff N; Brugman MH; Schlegelberger B; Suerbaum S; Krauter J; Ganser A; Heuser M
Genes Chromosomes Cancer; 2012 Jul; 51(7):689-95. PubMed ID: 22454318
[TBL] [Abstract][Full Text] [Related]
32. Biological and clinical consequences of NPM1 mutations in AML.
Heath EM; Chan SM; Minden MD; Murphy T; Shlush LI; Schimmer AD
Leukemia; 2017 Apr; 31(4):798-807. PubMed ID: 28111462
[TBL] [Abstract][Full Text] [Related]
33. Cytoplasmic expression of nucleophosmin 1 as a marker for diagnosing residual disease of acute myeloid leukemia.
Dai Q; Ren Y
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):205-11. PubMed ID: 23591014
[TBL] [Abstract][Full Text] [Related]
34.
Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
Turk J Haematol; 2018 Mar; 35(1):49-53. PubMed ID: 29129825
[TBL] [Abstract][Full Text] [Related]
35. Double Drop-Off Droplet Digital PCR: A Novel, Versatile Tool for Mutation Screening and Residual Disease Monitoring in Acute Myeloid Leukemia Using Cellular or Cell-Free DNA.
Rausch C; Rothenberg-Thurley M; Buerger SA; Tschuri S; Dufour A; Neusser M; Schneider S; Spiekermann K; Metzeler KH; Ziemann F
J Mol Diagn; 2021 Aug; 23(8):975-985. PubMed ID: 34020042
[TBL] [Abstract][Full Text] [Related]
36. Molecular methods used for detection of minimal residual disease following hematopoietic stem cell transplantation in myeloid disorders.
Elmaagacli AH
Methods Mol Biol; 2014; 1109():187-207. PubMed ID: 24473785
[TBL] [Abstract][Full Text] [Related]
37. Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia.
Du Pisani LA; Shires K
Hematol Oncol Stem Cell Ther; 2015 Sep; 8(3):106-14. PubMed ID: 26183674
[TBL] [Abstract][Full Text] [Related]
38. Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.
Selim AG; Moore AS
J Mol Diagn; 2018 Jul; 20(4):389-397. PubMed ID: 29689379
[TBL] [Abstract][Full Text] [Related]
39. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
40. Rapid and highly specific screening for NPM1 mutations in acute myeloid leukemia.
Oppliger Leibundgut E; Porret NA; Bienz Muggli M; Baumgartner H; Dahlhaus M; Baerlocher GM
Ann Hematol; 2013 Jan; 92(2):173-7. PubMed ID: 23161387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]